AUSTIN, Texas / Aug 06, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, Aug. 14 at 12:30 pm ET | 9:30 am PT in Boston, MA.
A live webcast and audio archive of the event may be accessed through the investor relations section of the Natera website at investor.natera.com. A replay of the event will be available shortly following the conference.
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 200 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.
| Last Trade: | US$173.06 |
| Daily Change: | 0.97 0.56 |
| Daily Volume: | 837,740 |
| Market Cap: | US$23.750B |
October 01, 2025 September 29, 2025 August 28, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
